Applications of 2'-Deoxyinosine in Industrial Manufacturing

As a manufacturer specialized in nucleoside ingredients, we supply 2'-Deoxyinosine for critical domains where precise standards, formulation, and integration at scale determine the success of bioprocessing and high-value synthesis. Below is an overview of proven sectors that rely on 2'-Deoxyinosine, detailing regulatory compliance, controlled usage, production step integration, and the core finished products at industrial scale.

1. Oligonucleotide Synthesis for Genetic Diagnostics

Nucleic acid testing and genetic diagnosis systems depend on custom oligonucleotides where 2'-Deoxyinosine functions as an ambiguous base, especially in primer and probe design to account for genetic variability in target sequences. Multinational IVD producers incorporate it for PCR and hybridization assays to enhance detection performance, working under tight specifications on nucleotide purity and batch traceability. Our facility directly supplies this grade for solid-phase DNA synthesis platforms at analytical scale and up, with documentation for each lot’s nucleoside content and residual solvent levels.

Industry compliance standards

• ISO 13485:2016 Medical Devices – QMS for IVDs
• US FDA 21 CFR 820 for medical device components
• European In Vitro Diagnostic Regulation (IVDR 2017/746) material traceability
• Ph. Eur. and USP compendial guidelines for nucleoside additives

Typical usage ratio

• 0.5–2.0 mol% replacement of standard dNTP in degenerate primers, precisely optimized by oligo sequence design and specificity requirements

Downstream process integration

• Batchwise loading into solid-phase synthesizer reactors after automated deprotection and before condensation with other protected nucleosides

Final product types

• Synthetic DNA primers and probes for RT-PCR, qPCR, LAMP, and microarray kits used in genetic diagnostics
• Custom oligonucleotide libraries for gene editing and mutation analysis

2. Enzyme Substrate Manufacturing for Research and Biotech Assays

2'-Deoxyinosine acts as a biochemical substrate in the preparation of DNA repair enzyme assay kits and nucleoside deaminase activity tests. Global enzymology labs and biotech suppliers use it in the controlled enzymatic conversion or hydrolysis reactions, supporting quantitative analysis of key DNA-modifying enzymes. We uphold batch homogeneity and contaminant profiles for research-grade supply to ensure consistent enzyme reaction kinetics and accurate assay calibration.

Industry compliance standards

• OECD Good Laboratory Practice (GLP) for biochemical reagents
• ISO 9001:2015 for laboratory chemical manufacturing
• Material Safety Data Sheet (MSDS) availability per REACH (EC 1907/2006)
• Raw material composition records for US NIH grant-supported research

Typical usage ratio

• Variable: 10–100 μM in final assay buffer, adjusted by enzyme activity and detection sensitivity in target assay protocols

Downstream process integration

• Direct dissolution into buffered solutions during reagent kit assembly; aliquoting under inert environment before lyophilization for shelf stability

Final product types

• DNA glycosylase activity assay kits
• Nucleoside deaminase enzymology panels
• High-throughput screening substrates for drug discovery platforms

3. Intermediates in Modified Nucleic Acid Pharmaceutical Manufacturing

API manufacturers synthesize drug candidates and active components for antiviral or gene therapy agents utilizing 2'-Deoxyinosine as a nucleoside intermediate. Its integration supports base-modified or prodrug design, especially where inosine moieties confer improved pharmacokinetics. Our GMP-compliant process controls impurity profiles, heavy metal content, and solvent residues for pharmaceutical-grade supply, ensuring downstream API synthesis maintains regulatory acceptability and process reproducibility at scale.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• EU GMP Part II for pharmaceutical starting materials
• US FDA DMF (Drug Master File) registration for nucleoside intermediates
• USP monographs for nucleoside-based therapeutics

Typical usage ratio

• Stoichiometric to slight excess (1.0–1.2 equivalents) relative to activated sugar or phosphoramidite agent during key coupling steps; fine-tuned for yield and downstream purification ease

Downstream process integration

• Chemical coupling with protected ribose or other sugar analogs via phosphoramidite or glycosylation chemistry; introduced after initial substrate functionalization and prior to ring closure/purification

Final product types

• Antiviral nucleoside analog precursors
• Base-modified DNA/RNA therapeutics
• Modified oligonucleotides for gene therapy pipelines

4. Biotechnological Media & Cell Culture Supplementation

Bioprocess manufacturers and research CDMOs add 2'-Deoxyinosine to high-performance cell culture media for mammalian and microbial systems employed in recombinant protein expression and hybridoma technology. Supplementation improves nucleotide availability, with fine-tuning based on cell line, medium formulation, and productivity targets. We supply cell culture–grade lots produced under ISO-certified processes, packaged contamination-free for easy scale-up in controlled bioreactor platforms.

Industry compliance standards

• ISO 9001:2015 for cell culture additive production
• USP <1043> Ancillary Materials for Cell, Gene, and Tissue-Engineered Products
• 21 CFR Part 210/211 for bulk additives in biologics production
• Raw material traceability per EMA Guideline on raw materials in biologics

Typical usage ratio

• 10–50 mg/L in basal culture medium, dosage optimized by cell type and specific requirements for growth rate or protein secretion levels

Downstream process integration

• Pre-mixing into sterile medium concentrates before final fill and sterile filtration; added prior to inoculation in cell expansion or protein production runs

Final product types

• Recombinant protein drug substances (e.g., monoclonal antibodies)
• Hybridoma-derived cell lines for antibody production
• Cell-based assay platforms and research bioproducts